Price
Target price
€48.40
€48.40
-1.220%
-0.6
-1.220%
€81.12
27.09.24 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
We can see a decrease in the price for Ultragenyx Pharmaceutical Inc.. Compared to yesterday it has lost -€0.600 (-1.220%).
With 28 Buy predictions and 1 Sell predictions Ultragenyx Pharmaceutical Inc. is one of the favorites of our community.
With a target price of 81 € there is a hugely positive potential of 67.36% for Ultragenyx Pharmaceutical Inc. compared to the current price of 48.4 €.
So far the community has only identified positive things for Ultragenyx Pharmaceutical Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -1.220% | -7.810% | -5.098% | 36.723% | 11.521% | -40.247% | 25.502% |
| Ironwood Pharmaceuticals | 1.120% | -6.250% | -17.431% | -59.322% | -64.706% | -68.696% | -54.082% |
| Arrowhead Pharmaceuticals Inc. | 0.280% | -5.395% | -20.429% | -28.989% | -37.411% | -68.572% | -28.455% |
| Novocure Ltd | 3.320% | -11.972% | -13.230% | -13.632% | -2.137% | -87.005% | -79.193% |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Barclays PLC from $83.00 to $81.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat